Ocular Therapeutix prices $100.1M public offering; updates wet AMD trial and cash runway into 2027

OCULAR THERAPEUTIX, INC

Priced underwritten public offering of 30.8M shares at $3.25/share for gross proceeds of $100.1M; net proceeds ~$93.6M.
Underwriters granted 30-day option for up to 4.62M additional shares; closing expected Dec 18, 2023.
Submitted SPA amendment to FDA to broaden SOL trial inclusion criteria and test single 450 µg implant; patient enrollment may begin Jan 2024.
Net proceeds plus existing cash expected to fund operations into 2027; additional capital needed for regulatory approval of AXPAXLI.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OCULAR THERAPEUTIX, INC entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at public offering price of $3.25 per share (effective 2023-12-13).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters
Value: public offering price of $3.25 per share
Effective: 2023-12-13

Exact text from the filing

On December 13, 2023, Ocular Therapeutix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 30,800,000 shares (the “Firm Shares”) of the Company’s common stock

View on SEC.gov

Browse all material agreements →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-125888

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.